Granules India Limited
NSE: GRANULESMarket Closed • NSE
Day range
52 week range
Granules India Limited closed at INR825.35 (+1.65%) on volume 1.11x its 20-day average, trading 10.64% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -10.9% QoQ
2026-07-30
DIVIDEND Announced
Dividend - Rs 1.75 Per Share
2025-07-31
DIVIDEND Announced
Dividend - Rs 1.50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 15.5%
Low Debt Profile: Debt-to-Equity is comfortable at 0.30x
High Cash Flow Conversion: CFO/PAT averaged 1.33x over last 3 years
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 30 Jul 2026 | Dividend | ₹1.75 / share | — | 30 Jul 2026 |
| 31 Jul 2025 | Dividend | ₹1.50 / share | — | 31 Jul 2025 |
| — | Dividend | ₹1.50 / share | — | 30 Jul 2024 |
| 03 Aug 2023 | Dividend | ₹1.50 / share | — | 03 Aug 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 03 Aug 2023 |
| 23 Aug 2022 | Buy Back | Buy Back | — | 22 Aug 2022 |
| — | Dividend | ₹0.75 / share | — | 19 Jul 2022 |
| 18 Feb 2022 | Dividend | ₹0.25 / share | — | 17 Feb 2022 |
| 25 Nov 2021 | Dividend | ₹0.25 / share | — | 24 Nov 2021 |
| 06 Aug 2021 | Dividend | ₹0.25 / share | — | 05 Aug 2021 |
| — | Dividend | ₹0.75 / share | — | 28 Jul 2021 |
| 09 Feb 2021 | Dividend | ₹0.25 / share | — | 08 Feb 2021 |
| 30 Oct 2020 | Dividend | ₹0.25 / share | — | 28 Oct 2020 |
| — | Dividend | ₹0.25 / share | — | 05 Aug 2020 |
| 29 Jul 2020 | Dividend | ₹0.25 / share | — | 28 Jul 2020 |
| 20 Mar 2020 | Buyback | Buyback | — | 19 Mar 2020 |
| 31 Jan 2020 | Dividend | ₹0.25 / share | — | 30 Jan 2020 |
| 02 Nov 2019 | Dividend | ₹0.25 / share | — | 31 Oct 2019 |
| — | Dividend | ₹0.25 / share | — | 21 Aug 2019 |
| 09 Aug 2019 | Dividend | ₹0.25 / share | — | 08 Aug 2019 |
| 08 Feb 2019 | Dividend | ₹0.25 / share | — | 07 Feb 2019 |
| 10 Nov 2018 | Dividend | ₹0.25 / share | — | 06 Nov 2018 |
| — | Dividend | ₹0.25 / share | — | 29 Aug 2018 |
| 02 Aug 2018 | Dividend | ₹0.25 / share | — | 01 Aug 2018 |
| 21 Feb 2018 | Dividend | ₹0.25 / share | — | 20 Feb 2018 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.[1]
IndiaHealthcare
Is Granules India Limited Shariah compliant?
Granules India Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (6.72%) complies with AAOIFI threshold (≤ 33%).
What is Granules India Limited's current valuation relative to peers?
Granules India Limited trades at a P/E of 30.7x compared to the sector median of 37x, and a Price-to-Book of 4.0x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.30x. Interest coverage is 7.8x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 3.7% while net profit growth averaged 3.5%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.